Stefin A Expression Screening for Breast Cancer Progression Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for managing pre-invasive breast cancer, such as ductal carcinoma in situ (DCIS), lack the ability to accurately predict which patients will progress to invasive cancer, leading to unnecessary aggressive treatments and potential side effects, as existing approaches focus on phenotypic or epigenetic changes to neoplastic cells rather than surrounding tissue markers.
Innovation Solution
A method involving the screening of Stefin A expression levels in myoepithelial cells to predict the risk of progression from pre-invasive to invasive breast neoplasia, where a decrease in Stefin A expression indicates an increased risk, allowing for personalized treatment decisions and potentially sparing treatment in patients with stable Stefin A levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods for managing pre-invasive breast cancer are used, then treatment decisions are made based on phenotypic or epigenetic changes to neoplastic cells, but the ability to accurately predict which patients will progress to invasive cancer is insufficient
Solution Approach 1:
The patent introduces an intermediary marker (Stefin A expression level in myoepithelial cells) that mediates the prediction of cancer progression risk. This marker serves as a bridge between the pre-invasive neoplasia state and the prediction of invasive cancer development, providing indirect but accurate information about progression risk that direct observation of neoplastic cell changes cannot provide.
2Object-affected harmful factors
If aggressive treatments are applied to all pre-invasive breast cancer patients, then potential side effects increase, but the ability to identify patients who truly need treatment decreases
Solution Approach 1:
The patent applies local quality by differentiating treatment needs based on local characteristics of individual patients' tumor microenvironment, specifically the Stefin A expression level in myoepithelial cells. Instead of uniform treatment, patients are stratified into high-risk and low-risk groups, with treatment intensity and type tailored to each patient's specific risk profile, thereby reducing unnecessary side effects while maintaining efficacy for those who need it.
3Measurement precision
If screening for Stefin A expression levels is implemented, then the ability to identify high-risk patients improves, but the complexity of the diagnostic process increases
Solution Approach 1:
The patent extracts a specific, measurable marker (Stefin A expression level in myoepithelial cells) from the complex tumor microenvironment to serve as the primary predictor of cancer progression. By focusing on this single extracted marker rather than analyzing all phenotypic and epigenetic changes, the diagnostic process becomes more streamlined while maintaining high prediction accuracy.
Data Source
AI summary
The present invention relates generally to a method of detecting a risk of the progression from a pre-invasive neoplasia of the glandular epithelium. More particularly, the present invention provides a method of detecting a risk of the progression from a pre-invasive breast neoplasia by screening for the level of expression of Stefin A in the myoepithelial cells. The method of the present invention is useful in a range of applications including, but not limited to, assessing a neoplastic condition, monitoring the progression of such a condition, predicting the likelihood of a subject progressing to a more advance disease state or informing decisions in relation to the design of treatment schedules.